2 results
Approved WMORecruiting
As part of your treatment, you will receive DUPIXENT. We would like to learn what the experiences of patients are with this medical product and if you notice any changes. The aim of the study is to better understand the characteristics of patients…
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2024-513770-22-00 check the CTIS register for the current data. Primary objective:• Evaluate the anti-tumor activity of GEN1046 as monotherapy and in combination with pembrolizumab in subjects with…